Treatment of genotype 3 cirrhotic patients with 12 weeks of Sofosbuvir/Velpatasvir with or without Ribavirin: Real life experience from Italy

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria


Treatment of genotype 3 cirrhotic patients with 12 weeks of Sofosbuvir/Velpatasvir with or without Ribavirin: Real life experience from Italy

	Reported by Jules Levin EASL 2019 April 10-14 Vienna